21. Electric Gene Therapy Approved A new cancer therapy that uses an electric pulse to aid in the injection of DNA into tumors is ready for use in Europe. By Kristen Philipkoski. Wired News http://www.wired.com/news/news/story/18552.html

22. BBC NEWS | Science/Nature | Gene Therapy Frees 'bubble Babies' The controversial medical field of gene therapy receives a boost with the successful treatment of a gene disorder. http://news.bbc.co.uk/hi/english/sci/tech/newsid_728000/728512.stm

CATEGORIES TV RADIO COMMUNICATE ... INDEX SEARCH You are in: Science/Nature News Front Page World UK ... Programmes SERVICES Daily E-mail News Ticker Mobile/PDAs Text Only ... Help EDITIONS Change to World Thursday, 27 April, 2000, 18:14 GMT 19:14 UK Gene therapy frees 'bubble babies' Scid children must live in sterile rooms The controversial medical field of gene therapy has received a boost with the successful treatment of a gene disorder. Two infants, aged 8 and 11 months, received new genetic material to combat a life-threatening disease called Severe Combined Immunodeficiency (Scid). Usually, patients with Scid are forced to live in tightly-controlled, sterile "bubbles" to avoid threats to their non-existent immune systems. A bone marrow transplant is the conventional treatment for such patients. But the two treated children have shown "striking" improvements and now live normally after their novel therapy. Gene therapy trials in the US have attracted much criticism over fears that patients were being harmed by the experimental treatments. Viral infection Scid is caused when a defective copy of a gene on the X chromosome is inherited.

23. Cancer Gene Therapy Supported by the International Society for Cancer gene therapy, this resource publishes original research and hosts diverse views. http://www.naturesj.com/cgt/index.html

24. The 2nd International Symposium On Molecular Diagnostics & Skin Gene Therapy, 27 Topics include chip technology and proteomics, targeting strategies, skin gene transfer, updates on vector systems, and inhibiting viral systems. March 27 29, 2003, D¼sseldorf, Germany. http://www.isgt-congress.org/

How to configure your browser for JavaScript >> March 27- 29, 2003 University Medical School Auditorium Building 13.55 Rooms 13A and 13B Moorenstr.5 40225 Duesseldorf. GERMANY Your browser is not configured correctly for use of this site. There are 2 reasons: 1. You have an up-to-date browser but have disabled some of the settings. To view this page we recommend you change the settings of your browser to enable JavaScript and Cookies. To configure your browser, see here ... Microsoft or Opera for a free download or contact your local IT administrator. Web browser requirements Support of JavaScript Support of cookies (registration only) Screen resolution: at least 800 by 600 pixel Your current configuration of your browser does not support this requirements. The ISGT 2003 will provide nine sessions with more than 65 seminars covering diverese aspects of gene therapy and molecular diagnostics i.e. chip technology and proteomics. Targeting strategies, skin gene transfer and its (pre-)clinical models, updates on vector systems and novel technologies in inhibiting viral diseases e.g. HIV, will be presented as well as immunization against infectious diseases and cancer. Controversial issues such as genetic patenting, ethics of gene replacement and safety issues will be offered for discussion. The symposium will commence with a keynote address on Thursday, 27th March at 9.00 o'clock at the Academy of Sciences (Akademie der Wissenschaften).

25. Pittsburgh Human Gene Therapy Center Fosters the growth and development of multidisciplinary preclinical and clinical research programs Category Science Biology Animal Mammal Human gene therapy......The mission of the The Pittsburgh Human gene therapy Center is to foster the growthand development of multidisciplinary preclinical and clinical research http://www.pitt.edu/~rsup/phgt/

This site is now incorporated within The Molecular Medicine Institute. Please Click Here

26. Curriculum Vitae For Phyllis Frosst Postdoctoral fellow with experience in gene therapy, cell biology and human genetics. http://www.scripps.edu/~phyllis/

Curriculum Vitae Phyllis Frosst, Ph.D. The Scripps Research Institute 10550 N. Torrey Pines Rd. Imm19 La Jolla, CA 92037 Work Tel: 858-784-9182 Fax: 858-784-8472 Email: phyllis@scripps.edu www.scripps.edu/~phyllis/ Current Position: Feb. 2002 - present Postdoctoral Fellow Adenoviral Mediated Gene Therapy Laboratory of Dr. Glen Nemerow Immunology Department The Scripps Research Institute, La Jolla CA Education: Aug. 1995- April 2001 Ph.D. in Macromolecular and Cellular Structure and Chemistry Cell Biology Department The Scripps Research Institute, La Jolla CA Dissertation: Investigation of Tpr, a large coiled-coil protein of the Nuclear Pore Complex Advisor: Dr. Larry Gerace, Professor Departments of Cell Biology and Molecular Biology. July 1994- July 1995 McGill University, Montreal, Quebec, Canada

27. UNC Gene Therapy Center The gene therapy Center at the University of North Carolina at Chapel http://www.med.unc.edu/genether/welcome.htm

This page utilizes frames.

28. Alberta Gene Therapy Group A network of researchers looking to foster collaboration in several therapeutic fields.Category Science Biology Animal Mammal Human gene therapy......Welcome to the Alberta gene therapy Group Home Page. News. Conference Report 1995Alberta gene therapy Meeting. Abstracts - 1995 Alberta gene therapy Meeting. http://www.ualberta.ca/~britchie/agtg.html

Welcome to the Alberta Gene Therapy Group Home Page The Alberta Gene Therapy Group was born during a meeting organised by Lung-Ji Chang from the University of Alberta and Norman Wong from the University of Calgary held at the Holiday Inn, Red Deer, Alberta, November 23, Thursday, 1995. The Group is made up of people from the Unversity of Alberta , the Unversity of Calgary , the Alberta Cancer Board, the Alberta Heritage Foundation for Medical Research , the Alberta Research Council , the Alberta Science and Research Authority Alberta Health and Wellness , and MDS Health Ventures Ltd. They are all interested in research in the field of gene therapy. Contact information is provided below to foster collaboration. The group has been inactive recently. ... created by related sites Biochemistry , University of Alberta Department of Medical Microbiology and Immunology , University of Alberta Oncology , University of Alberta Department of Medical Genetics , University of Alberta Cell Biology , University of Alberta Membrane Proteins Research Group , University of Alberta Molecular and Cell Biology of Lipids , University of Alberta MRC Group in Protein Structure and Function , University of Alberta Protein Engineering Network of Centres of Excellence , University of Alberta Molecular Mechanisms of Growth Control , University of Alberta Institute for Biomolecular Design , University of Alberta Biochemistry and Molecular Biology , University of Calgary Cancer Biology Research Group , University of Calgary University of Alberta

29. QIAGEN - Innovation Working For You Products and services for life science research, molecular diagnostics, genomics, and gene therapy. http://www.qiagen.com

MacNS4SizeFix(["P", "LI", "H1", "H2", "H3", "TD", "UL"], ["footnote.all", "legend.all", "superscript.all", "subscript.all", "linespace.all", "orderInfo.all", "orderInfoKitName.all", "itemTitle.all", "telNoTitle.all", "telNo.all", "telNoNumber.all" ]); Product guide siRNA Order DNA oligos Ordering ... QIAcabinet on-site stocking Technical Resources MSDS Reference database QIAGEN News Vector sequences ... Scientific information Contact Technical service Customer service Worldwide contacts About QIAGEN Investor relations What we do Jobs The BioRobot EZ1 System A complete, easy-to-use system for nucleic acid purification from a wide range of clinical samples. previous articles Highly efficient multiplex PCR using novel reaction chemistry QIAGEN News 2003 No. 1 available Discover new solutions for highly sensitive array detection and multiplex PCR, plus new products for gene silencing, fully automated nucleic acid purification, and more! Get consistent real-time quantitative PCR and RT-PCR results!

30. Licensing Medical Implanting Technology To Biotech And Pharma Companies Implants for pharmaceutical and gene therapy controlled release pellets, brachytherapy seeds, and chip and nanodevices. http://www.NjeX.com/

NjeX Implant Introducing Systems for the Future's Medical Implant Devices Convenient and Cost-Effective Implanting of: Controlled Release Drug/Gene Therapy Devices Various Chip and Nano-Device Implants Radionuclide and Thermo-Active Seeds, or... Your New Implant Device? Privacy, terms and conditions

31. Department Of Health: Gene Therapy Advisory Committee Advises on the ethical acceptability of proposals for gene therapy research on humans and on developments in gene therapy research. Provides information on the Committee's work and publications. http://www.doh.gov.uk/genetics/gtac/index.htm

A-Z site index Search Links Contact DH ... DH Home You are here: About the Department Non-departmental public bodies GTAC About GTAC What's new 'Flagging' project - monitoring patients Applying to GTAC to conduct clinical trials ... Contact GTAC Gene Therapy Advisory Committee (GTAC) THE GENE THERAPY ADVISORY COMMITTEE ISSUES ADVICE ON X-SCID GENE THERAPY TRIALS Senior Scientist - Genetic Science Policy STATEMENT FROM THE GENE THERAPY ADVISORY COMMITTEE The Gene Therapy Advisory Committee (GTAC)'s terms of reference are: To consider and advise on the acceptability of proposals for gene therapy research on human subjects, on ethical grounds, taking account of the scientific merits of the proposals and the potential benefits and risks. To work with other agencies which have responsibilities in this field, including local research ethics committees, and agencies with statutory responsibilities - the Medicines Control Agency, the Health and Safety Executive and the Department of the Environment. To provide advice to United Kingdom Health Ministers on developments in gene therapy research and their implications.

32. Welcome To TriLink BioTechnologies Services for researchers in the fields of gene therapy, nucleoside chemotherapy, oligonucleotide therapy and diagnostics. News and product information. http://www.trilinkbiotech.com/

About TriLink Products Technical Information Ordering ... Search The source for superior quality modified oligonucleotides and modified nucleoside triphosphates. About TriLink Technical Information Ordering What's New ... Trademark Information

33. Cell Transplants International Notfor-profit medical research foundation working to find a treatment for muscular dystrophy and other genetic diseases through cell/gene therapy. Site describes treatments and clinical trials. http://www.celltherapy.com/

Home What's New Videos Patents FAQ ... Contact Us Established in 1997, Cell Transplants International, LLC (CTI) is dedicated to finding a treatment for muscular dystrophy and other hereditary degenerative diseases. Our current work focuses on Duchenne muscular dystrophy (DMD), Becker, and limb-girdle muscular dystrophies. CTI's pioneering work has developed over the past 28 years and is the first research into human cell/gene therapy. It is the only human genome therapy in existence. Extensive experience in large-scale production of pure myoblasts and intellectual property encompassing the production, sale, and use of myoblasts give CTI a unique advantage over its competitors. Be sure to visit the What's New section to read about our latest development of Myoblast Transfer Therapy (MTT) into the heart.

34. Department Of Health gene therapy Advisory Committee The information on this page is now on. http//www.doh.gov.uk/genetics/gtac/index.htm.Please update your bookmarks. Top. http://www.doh.gov.uk/genetics/gtac.htm

A-Z site index Search Links Contact DH ... DH Home You are here: About the Department Non-departmental public bodies GTAC Gene Therapy Advisory Committee The information on this page is now on http://www.doh.gov.uk/genetics/gtac/index.htm Please update your bookmarks Top

35. Aastrom, Inc. Develops proprietary process technologies and devices for cell therapy applications, including stem cell therapies and gene therapy. (Nasdaq ASTM). http://www.aastrom.com/

36. Charitable Medical Air Travel And Housing For Gene Therapy Patients Charitable medical air transportation and housing arrangements for gene therapy patients and their families through Angel Flight America and the National Association of Hospital Hospitality Houses. http://www.genetherapytravel.org/

www.GeneTherapyTravel.org Charitable travel and housing arrangements through Angel Flight America and the National Association of Hospital Hospitality Houses. There are two key challenges for many who must travel a long distance from home for specialized gene therapy evaluation, diagnosis or treatment. They are: Long-distance Travel. There is charitable long-distance medical air transportation available to help - whether it is just one trip or multiple round trips. Follow the link to go to www.PatientTravel.org or call their Helpline at Away from Home Guest Housing. There are hundreds of Hospital Hospitality Guest Houses able to provide assistance to patients and families. Follow the link to go to www.nahhh.org - the National Association of Hospital Hospitality Houses - for housing directory assistance, or call their Helpline at National Association Hospital Hospitality Houses, Inc Lodging Assistance for Persons Receiving Medical Treatment Away From Home CONTACTING THE ORGANIZATIONAL SPONSORS OF THIS SITE: Mercy Medical Airlift for: National Patient Travel Center (Serving Angel Flight America) 4620 Haygood Road, Ste. 1

37. UMHS Center For Gene Therapy The center links basic science, clinical investigation and technology transfer endeavors in the area of gene therapy, while also serving as a resource for information and education. http://www.med.umich.edu/cgt/

University of Michigan Medical System Center for Gene Therapy Search the CGT Website June 18, 2002 Announcement of next round of Pilot Grant Funding. Click here for details. Applications due Sept. 1, 2002. Feb. 25, 2002 Addition of to Clinical Trials Program Resources Seminar Series Membership Application Intramural Grant Program ... Search Site Updated 10/21/2002 Mission The Center for Gene Therapy at the University of Michigan Medical Center was created to link basic science, clinical investigation and technology transfer. The Center fosters a multidisciplinary approach to new research as well as collaborative research endeavors in the area of gene therapy; extends the services of existing and newly created research cores to investigators; and serves as a resource for information and education. Scope of Activities To aid medical researchers, we have divided the Center into four programs. Each program offers products and services to aid the medical researcher here at Michigan and elsewhere. The products and services are : Gene Vector Program The Vector Core Laboratory Clinical Trials Program Regulatory Application Assistance Educational Program Administrative Program Cellular Therapy Development Grant Program Background

38. Gene Therapy - An Overview gene therapy An Overview. BIO. Biotechnology in Perspective. Washington,DC Biotechnology Industry Organization, 1990. Altered Genes. gene therapy. http://www.accessexcellence.org/AB/IWT/Gene_Therapy_Overview.html

Gene Therapy - An Overview BIO. "Biotechnology in Perspective." Washington, D.C.: Biotechnology Industry Organization, 1990. Altered Genes Each of us carries about half a dozen defective genes. We remain blissfully unaware of this fact unless we, or one of our close relatives, are amongst the many millions who suffer from a genetic disease. About one in ten people has, or will develop at some later stage, an inherited genetic disorder, and approximately 2,800 specific conditions are known to be caused by defects (mutations) in just one of the patient's genes. Some single gene disorders are quite common - cystic fibrosis is found in one out of every 2,500 babies born in the Western World - and in total, diseases that can be traced to single gene defects account for about 5% of all admissions to children's hospitals. In the U.S. and Europe, there are exciting new programs to 'map' the entire human genome - all of our genes. This work will enable scientists and doctors to understand the genes that control all diseases to which the human race is prone, and hopefully develop new therapies to treat and predict diseases. Diseases of Genetic Origin Most of us do not suffer any harmful effects from our defective genes because we carry two copies of nearly all genes, one derived from our mother and the other from our father. The only exceptions to this rule are the genes found on the male sex chromosomes. Males have one X and one Y chromosome, the former from the mother and the latter from the father, so each cell has only one copy of the genes on these chromosomes. In the majority of cases, one normal gene is sufficient to avoid all the symptoms of disease. If the potentially harmful gene is recessive, then its normal counterpart will carry out all the tasks assigned to both. Only if we inherit from our parents two copies of the same recessive gene will a disease develop.

39. Viewsonic Discovers and develops nonsurgical gene therapy products for treating cardiovascular diseases, including coronary artery disease, peripheral vascular disease, congestive heart failure and heart attack. (Nasdaq CLTX). http://www.collateralthx.com/

http://www.berlex.com http://www.berlex.com

40. Program In Human Gene Therapy Facilitates the application of basic and preclinical research to the treatment of human disease through Category Science Biology Animal Mammal Human gene therapy......Located in the UCSD School of Medicine and home to the Program in Human gene therapy.Welcome to the UCSD School of Medicine's Program in Human gene therapy. http://medicine.ucsd.edu/gt/

THE CELLULAR AND MOLECULAR MEDICINE - EAST building Located in the UCSD School of Medicine and home to the Program in Human Gene Therapy Welcome to the UCSD School of Medicine's Program in Human Gene Therapy. Our goals are to: Catalyze basic research into the genetics and cell biology of gene transfer Facilitate the application of basic and pre-clinical research to the treatment of human disease The Program includes a Vector Development core laboratory . Functions include: The preparation of research-grade gene transfer materials, including the production of retroviral, adenoviral, adeno-associated and herpes viral vectors Assistance at all stages of vector development, including advice on the design of vector constructs, plasmid preparation, development of producer cells, and production of virus. The production of clinical-grade vectors for human studies is now provided by Molecular Medicine, LLC. Molecular Medicine, LLC is a joint venture between The University of California, San Diego and Boehringer Mannheim (Roche). In addition the Program is proud to sponsor the Gene Therapy Seminar Series.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 2     21-40 of 169    Back | 1  | 2  | 3  | 4  | 5  | 6  | 7  | 8  | 9  | Next 20